Form 4: Baker Bros. Advisors LP Reports Acquisition of IGM Biosciences Stock Units

Baker Bros. Advisors LP reports the acquisition of restricted stock units in IGM Biosciences on behalf of several entities due to director compensation.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, reported the acquisition of 953 restricted stock units (RSUs) of IGM Biosciences, Inc. on March 31, 2025.
• The RSUs were issued to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, in lieu of director retainer fees of $11,500 under IGM Biosciences' Outside Director Compensation Policy.
• The reported transaction does not represent a direct pecuniary interest for Felix J. Baker, Julian C. Baker, Baker Bros. Advisors (GP) LLC, or Baker Bros. Advisors, LP, except to the extent of their indirect pecuniary interest through their ownership in the Funds.
• After the transaction, Baker Bros. Advisors LP and related parties indirectly hold 356,095 and 3,762,409 shares of IGM Biosciences common stock.
• The reporting persons, other than Felix J. Baker, are deemed directors by deputization of IGM Biosciences.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating continued involvement and alignment with the company's equity. The sentiment is neutral to slightly positive.

Positives

• The acquisition of RSUs reflects continued involvement and alignment of Baker Bros. Advisors LP with IGM Biosciences.
• The acceptance of RSUs in lieu of cash retainer fees demonstrates a commitment to the company's equity.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Comparison to Industry Standards

• Director compensation in the form of stock options and restricted stock units is a common practice in the biotechnology industry to align the interests of directors with those of shareholders.
• The amount of RSUs granted in lieu of cash compensation appears to be within the typical range for director compensation at similar-sized biotech companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning director interests with company performance.

Key Dates

Keywords

IGM Biosciences, Baker Bros. Advisors LP, restricted stock units, RSUs, director compensation, beneficial ownership, Form 4, equity securities